PL363110A1 - Kompozycja zawierająca kamptotecynę i pochodną pirymidyny do leczenia raka - Google Patents

Kompozycja zawierająca kamptotecynę i pochodną pirymidyny do leczenia raka

Info

Publication number
PL363110A1
PL363110A1 PL01363110A PL36311001A PL363110A1 PL 363110 A1 PL363110 A1 PL 363110A1 PL 01363110 A PL01363110 A PL 01363110A PL 36311001 A PL36311001 A PL 36311001A PL 363110 A1 PL363110 A1 PL 363110A1
Authority
PL
Poland
Prior art keywords
camptothecin
cancer
treatment
pyrimidine derivative
composition
Prior art date
Application number
PL01363110A
Other languages
English (en)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of PL363110A1 publication Critical patent/PL363110A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL01363110A 2000-02-28 2001-02-26 Kompozycja zawierająca kamptotecynę i pochodną pirymidyny do leczenia raka PL363110A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18537800P 2000-02-28 2000-02-28
US20893800P 2000-06-05 2000-06-05

Publications (1)

Publication Number Publication Date
PL363110A1 true PL363110A1 (pl) 2004-11-15

Family

ID=26881090

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01363110A PL363110A1 (pl) 2000-02-28 2001-02-26 Kompozycja zawierająca kamptotecynę i pochodną pirymidyny do leczenia raka

Country Status (28)

Country Link
US (3) US6503889B2 (pl)
EP (1) EP1278518B1 (pl)
JP (1) JP2003523980A (pl)
KR (1) KR100717916B1 (pl)
CN (1) CN1424912A (pl)
AT (1) ATE344670T1 (pl)
AU (1) AU785467B2 (pl)
BR (1) BR0108728A (pl)
CA (1) CA2401191C (pl)
CY (1) CY1105803T1 (pl)
CZ (1) CZ298259B6 (pl)
DE (1) DE60124387T2 (pl)
DK (1) DK1278518T3 (pl)
EA (1) EA005619B1 (pl)
EE (1) EE200200471A (pl)
ES (1) ES2273841T3 (pl)
HR (1) HRP20020658A2 (pl)
HU (1) HUP0300848A3 (pl)
IL (1) IL150953A0 (pl)
MX (1) MXPA02008355A (pl)
NO (1) NO324772B1 (pl)
NZ (1) NZ520593A (pl)
PL (1) PL363110A1 (pl)
PT (1) PT1278518E (pl)
SK (1) SK12242002A3 (pl)
TW (1) TWI239841B (pl)
WO (1) WO2001062235A2 (pl)
YU (1) YU64602A (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
WO2004034787A1 (en) * 2002-10-17 2004-04-29 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
MXPA06013902A (es) * 2004-05-28 2007-01-26 Pfizer Prod Inc Procedimiento para tratar el crecimiento de celulas anormal.
MXPA06013952A (es) * 2004-06-04 2007-02-08 Smithkline Beecham Cork Ltd Metodo para el tratamiento de cancer.
CA2569277A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
CA2604192A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
BRPI0613796A2 (pt) * 2005-06-07 2011-02-15 Univ Yale composicões farmacêuticas e seus usos, e métodos de tratamento de cáncer e outras condições ou estados patológicos, por meio do uso de clevudina (lfmau) e telbivudina (ldt)
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
EP2427179A4 (en) 2009-05-04 2013-09-11 Psivida Inc POROUS PARTICLES FOR THE RELEASE OF SILICIUM MEDICINES
EP3117709B1 (en) * 2010-03-12 2018-08-01 Genzyme Corporation Combination therapy for treating breast cancer
RU2640918C2 (ru) 2010-11-01 2018-01-12 Псивида Юэс, Инк. Биоразлагаемые устройства на основе кремния для доставки терапевтических агентов
CN105025928A (zh) 2013-03-15 2015-11-04 普西维达公司 用于递送治疗剂的可生物蚀解的硅基组合物
WO2025247281A1 (zh) * 2024-05-28 2025-12-04 上海靶康联耀生物医药科技有限公司 一种药物组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS57116015A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Antitumor agent
JPS57116074A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS595188A (ja) 1982-06-30 1984-01-12 Yakult Honsha Co Ltd １０−ヒドロキシカンプトテシンの製造法
JPS5951289A (ja) 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
CA1332413C (en) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
JP2524804B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体及びその製造法
JP2524803B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体およびその製造法
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
DK0540099T3 (da) 1991-10-29 1996-06-17 Glaxo Wellcome Inc Vandopløselige camptothecinderivater
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5670500A (en) 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
DE69635560T2 (de) 1995-06-21 2006-08-17 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Camptothecinanaloge, Verfahren zur ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
IL143920A0 (en) * 1998-12-31 2002-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds

Also Published As

Publication number Publication date
HRP20020658A2 (en) 2004-12-31
US6664242B2 (en) 2003-12-16
HUP0300848A2 (hu) 2003-08-28
YU64602A (sh) 2005-06-10
WO2001062235A2 (en) 2001-08-30
US20020068743A1 (en) 2002-06-06
NZ520593A (en) 2004-10-29
ATE344670T1 (de) 2006-11-15
WO2001062235A3 (en) 2002-11-14
TWI239841B (en) 2005-09-21
CA2401191A1 (en) 2001-08-30
CZ298259B6 (cs) 2007-08-08
EP1278518A2 (en) 2003-01-29
NO20024076L (no) 2002-08-27
ES2273841T3 (es) 2007-05-16
EP1278518B1 (en) 2006-11-08
IL150953A0 (en) 2003-02-12
DE60124387T2 (de) 2007-10-11
DK1278518T3 (da) 2007-01-15
DE60124387D1 (de) 2006-12-21
HUP0300848A3 (en) 2005-03-29
US20030096789A1 (en) 2003-05-22
US6503889B2 (en) 2003-01-07
EA200200922A1 (ru) 2003-04-24
JP2003523980A (ja) 2003-08-12
CA2401191C (en) 2006-05-02
NO20024076D0 (no) 2002-08-27
KR100717916B1 (ko) 2007-05-11
EA005619B1 (ru) 2005-04-28
PT1278518E (pt) 2007-01-31
CZ20022892A3 (cs) 2002-11-13
BR0108728A (pt) 2003-12-30
KR20020082856A (ko) 2002-10-31
SK12242002A3 (sk) 2003-02-04
MXPA02008355A (es) 2002-12-13
CN1424912A (zh) 2003-06-18
NO324772B1 (no) 2007-12-10
AU6011101A (en) 2001-09-03
EE200200471A (et) 2003-12-15
AU785467B2 (en) 2007-07-26
CY1105803T1 (el) 2011-02-02
US20020091132A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
IL150953A0 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
MY140398A (en) 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
EP1409547A4 (en) METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING THE IMMUNE SYSTEM, IN PARTICULAR FOR USE IN CANCER THERAPY
MY128362A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
AU2162202A (en) Antitumor therapy comprising distamycin derivatives
JO2199B1 (en) Replaced pyrrols
EP1221945A4 (en) METHOD AND PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FOR THE ADMINISTRATION OF ADENOSINE
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
DK1161254T3 (da) Behandling af autoimmune sygdomme med en ekstrakt af amerikansk ginseng
WO2002076397A3 (en) Telomerase inhibitors and methods of their use
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
PL365075A1 (pl) Połączenia dalfopristyny/quinupristyny z cefpiromem
IL160412A0 (en) Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)